A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer
Phase of Trial: Phase I/II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Endometrial cancer; Prostate cancer
- Focus Adverse reactions
- 14 Aug 2018 Planned primary completion date changed from 1 Nov 2020 to 14 Oct 2020.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.
- 04 Jul 2018 New trial record